Text Size

Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Groupe Hospitalier Pitie-Salpetriere.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Institut National de la Santé Et de la Recherche Médicale, France
Information provided by:
Groupe Hospitalier Pitie-Salpetriere
ClinicalTrials.gov Identifier:
NCT00289159
First received: February 8, 2006
Last updated: NA
Last verified: September 2005
History: No changes posted
  Purpose

To determine wether multimodal MRI (conventinal T1 and T2 sequences, diffusion, magnetization transfer, spectroscopy) is reproducible; to follow up a cohort of patients with early remmittent MS after treatment with interferon.


Condition Phase
Multiple Sclerosis
 Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Follow Up by Multimodal MRI of a Cohort of Patients With Early Remitting Multiple Sclerosis (REPROMMS Study).

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Groupe Hospitalier Pitie-Salpetriere:

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • MS patients according to Poser's criteria
  • Remitting evolution (less than two years of evolution)
  • Aged 18-50
  • Immunomodulatory treatment indicated

Exclusion Criteria:

  • Unable to perform MRI
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00289159

Sponsors and Collaborators
Groupe Hospitalier Pitie-Salpetriere
Institut National de la Santé Et de la Recherche Médicale, France
Investigators
Principal Investigator: Ayman Tourbah, MD, PhD AP-HP
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00289159     History of Changes
Other Study ID Numbers: RBM0110
Study First Received: February 8, 2006
Last Updated: February 8, 2006
Health Authority: France: Ministry of Health

Keywords provided by Groupe Hospitalier Pitie-Salpetriere:
aged 18-50
remitting evolution
less than two years of evolution
MS patients

Additional relevant MeSH terms:
Multiple Sclerosis
Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
 Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on June 17, 2013